Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Juno Therapeutics
Juno Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
AbbVie and Gedeon Richter join forces to advance neuropsychiatric target R&D
The companies will aim to discover and progress targets for neuropsychiatric disorders
Containment in a high potent manufacturing facility
Throughout the pharmaceutical industry, there is a lack of consistency regarding the assignment of Occupational Exposure Limits (OELs) to specific bands
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Celgene set to become leader in CAR-T space
According to GlobalData, a data and analytics company, Celgene’s acquisition of Juno Therapeutics puts the company in a good position to be a frontrunner in the chimeric antigen receptor-T cell space
Research & Development
Juno Therapeutics and WuXi AppTec announce new company to develop novel cell-based cancer immunotherapies in China
JW Biotechnology will Leverage Juno's immuno-oncology expertise and assets and WuXi AppTec's R&D and manufacturing platform
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Finance
Juno Therapeutics acquires German biotech Stage Cell Therapeutics for US$81m
Gaining access to transformative cell selection and activation capabilities
Research & Development
US cancer research centres launch biotech start-up
Juno Therapeutics will have US$120m initial investment and develop cancer immunotherapy products
Subscribe now